Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APVO101 in pediatric hemophilia B
NCT03855280Phase 3Completed
- Sponsor
- Medexus Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 3 trial of coagulation factor ix recombinant in hemophilia B (HB), sponsored by Medexus Pharmaceuticals. Started Jan 2020; status: completed.
02
Drugs
coagulation factor ix recombinant
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT03855280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03855280.